Vera Therapeutics
Market cap $1.89B 72.3M shares (10-Q, Oct 29, 2026) × $26.20 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- Atacicept PIONEER Ph2 readout4Q 2026Atacicept PIONEER Ph2 readout, 4Q 2026, notable
- Oxford loan corporate updateMar 31, 2027Oxford loan corporate update, Mar 31, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
MAU868
VT-109
- Undisclosed indication
Capital (as filed)
- Cash
- $55.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $329M Sep 30, 2026
- Operating cash flow
- −$99.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $384M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-06 UPDATE: Vera Therapeutics (VERA) - The First Sales Receipt 🔒 Paid
- 2026-09-16 UPDATE: Vera Therapeutics (VERA) - The Confirmatory Data Lands, and It’s Not Close 🔒 Paid
- 2026-08-11 UPDATE: Vera Therapeutics (VERA) - The Post-Approval Hangover 🔒 Paid
- 2026-07-07 UPDATE: Vera Therapeutics (VERA) - The Lazarus Drug Gets Its Label 🔒 Paid
- 2026-06-02 UPDATE: Vera Therapeutics (VERA) - The Full Approval Clock Just Moved Up a Year
- 2026-03-07 UPDATE: Vera Therapeutics (VERA) - VERA Adds an M&A Heavyweight to the Board 🔒 Paid
- 2026-02-28 UPDATE: Vera Therapeutics (VERA) - FY25 Wrap-Up 🔒 Paid
- 2026-01-07 UPDATE: Vera Therapeutics (VERA) Hits the Accelerator – FDA Grants Priority Review 🔒 Paid
- 2025-12-16 Vera Therapeutics (VERA): Scientific Due Diligence for Atacicept and Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Vera Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-16 Watch Vera Therapeutics (VERA): Scientific Due Diligence for Atacicept and Pipeline Phase 3 data is real and M&A appeal is high, but the post-financing reset and potential priced-in Phase 3 pop warrant waiting for a dip below the $42.50 offering price before entering.
- 2026-01-07 Hold UPDATE: Vera Therapeutics (VERA) Hits the Accelerator – FDA Grants Priority Review FDA Priority Review confirms the data package and tightens the timeline to a July 7, 2026 PDUFA date; thesis tracking perfectly so holders should sit tight while new entrants wait for post-pop volatility to settle.
- 2026-02-28 Hold UPDATE: Vera Therapeutics (VERA) - FY25 Wrap-Up Strong $714M cash balance de-risks the commercial launch timeline; fundamentals tracking well ahead of the July PDUFA and 1H 2026 PIONEER data, with dips below $42.50 offering price representing solid entry points.
- 2026-03-07 Hold UPDATE: Vera Therapeutics (VERA) - VERA Adds an M&A Heavyweight to the Board Appointment of career dealmaker Christopher Hite to the board reinforces the M&A thesis; stance unchanged as holders wait for the July PDUFA binary event.
- 2026-06-02 Buy core UPDATE: Vera Therapeutics (VERA) - The Full Approval Clock Just Moved Up a Year FDA alignment to pull the confirmatory eGFR readout forward to Q3 2026 shortens the full-approval path by a year and widens the first-mover gap on Vertex, while shares at $31.26 sit well below the $42.50 institutional entry price.
- 2026-07-07 Buy core UPDATE: Vera Therapeutics (VERA) - The Lazarus Drug Gets Its Label FDA granted accelerated approval to TRUTAKNA on the exact PDUFA date with no AdCom and no safety restrictions, validating the first-mover thesis; holders should sit tight through the Q3 eGFR readout and M&A window rather than taking full profits.
- 2026-08-11 Buy core UPDATE: Vera Therapeutics (VERA) - The Post-Approval Hangover Despite a 26.5% post-approval pullback and accelerating burn, the thesis is intact with the moat-defining ORIGIN 3 eGFR readout imminent; shares at $31.58 appear to have priced out the approval entirely while pricing in none of the confirmatory data.
- 2026-09-16 Buy core UPDATE: Vera Therapeutics (VERA) - The Confirmatory Data Lands, and It's Not Close ORIGIN 3 final analysis delivered a flat eGFR slope (-0.6 vs -5.6 mL/min/year) and 76% reduction in kidney disease progression, retiring the last major scientific risk; the story now re-rates on quarterly revenue prints rather than press releases.
- 2026-11-06 Buy core UPDATE: Vera Therapeutics (VERA) - The First Sales Receipt First revenue of $10.3M, accelerating patient start forms to ~700, and on-time sBLA filing confirm the launch is tracking; the bear case is now the ~$100M quarterly burn against ~$459M pro forma cash rather than the science.
- Long call · opened Jun 3, 2026 at $31.27 · -16.2% vs XBI +11.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies.”
matched to Atacicept (PIONEER) · readout other
-
-
-
“Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.”
matched to Atacicept (PIONEER) · readout other
-
-
-
“In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies.”
matched to Atacicept (PIONEER) · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (27)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 5, 2026ReleaseVera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateTRUTAKNA's first revenue quarter clears $10M on ~700 patient start forms, the ORIGIN 3 data lands in the NEJM, the sBLA is filed, and PIONEER flashes its first signal — yet VERA trades 29% below the December offering price.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Oct 22, 2026ReleaseVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedBD extracted 1 program update from this document → VERA pipeline
- Oct 20, 2026ReleaseVera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastBD extracted 1 program update from this document → VERA pipeline
- Oct 2, 2026ReleaseVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN KBD extracted 1 program update from this document → VERA pipeline
- Sep 15, 2026ReleaseVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy→ BD updateSummary on the 8-K
- Sep 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateORIGIN 3's final eGFR analysis just delivered the data I've been tracking all year: TRUTAKNA stabilized kidney function through two years with a 76% risk reduction in composite kidney progression — the confirmatory win that converts a conditional accelerated label into a full-approval story, and clears the last major scientific binary for the Lazarus drug thesis.BD extracted 1 program update from this document → VERA pipeline
- Sep 1, 2026ReleaseVera Therapeutics to Participate at Upcoming Investor Conferences
- Aug 10, 2026ReleaseVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 202610-QQuarterly report
- Jul 9, 2026ReleaseVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
- Jul 9, 20268-KCurrent report: officer / director change
- Jul 7, 2026ReleaseVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA NephropathyBD extracted 1 program update from this document → VERA pipeline
- Jul 7, 20268-KCurrent report: other events
- Jun 2, 2026ReleaseVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyBD extracted 1 program update from this document → VERA pipeline
- Jun 2, 20268-KCurrent report: other events
- May 26, 20268-KCurrent report: shareholder vote
- May 7, 2026ReleaseVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 9, 2026DEFA14AProxy soliciting material
- Apr 9, 2026DEF 14AProxy statement
- Mar 9, 20268-KCurrent report: officer / director change
- Mar 5, 2026SCHEDULE 13D/A13D amendment
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 30, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 9, 2026ARSAnnual report to shareholders
- Apr 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 27, 2026SCHEDULE 13G/A13G amendment
- Mar 11, 2026SCHEDULE 13GPassive >5% holder (13G)